MicroRNAs in Sarcopenia: A Systematic Review

Katsunori Yanai¹, Shohei Kaneko¹, Hiroki Ishii¹, Akinori Aomatsu¹,², Kiyonori Ito¹, Keiji Hirai¹, Susumu Ookawara¹, Kenichi Ishibashi³ and Yoshiyuki Morishita¹*

¹ Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ² Division of Intensive Care Unit, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ³ Department of Medical Physiology, Meiji Pharmaceutical University, Tokyo, Japan

Sarcopenia, which is characterized by the loss of skeletal muscle, has been reported to contribute to development of physical disabilities, various illnesses, and increasing mortality. MicroRNAs (miRNAs) are small non-coding RNAs that inhibit translation of target messenger RNAs. Previous studies have shown that miRNAs play pivotal roles in the development of sarcopenia. Therefore, this systematic review focuses on miRNAs that regulate sarcopenia.

Keywords: sarcopenia, microRNA, myotube, myocyte, myoblast, systematic review

INTRODUCTION

Sarcopenia, defined by the loss of skeletal muscle loss, contributes to developing physical disabilities, various illnesses, and increasing mortality (1, 2). MicroRNAs (miRNAs) have attracted attention as potential biomarkers and targets for specific therapies. MiRNAs are small non-coding RNAs (21–25 bases) that are not translated into proteins but inhibit the function of their target messenger RNAs (mRNAs) by destabilizing them and inhibiting their translation (3, 4). Previous studies have shown that miRNAs play pivotal roles in the development of sarcopenia (1–82). Therefore, this systematic review focuses on miRNAs that regulate sarcopenia.

MECHANISM OF THE DEVELOPMENT OF SARCOPENIA

Several factors, including chronic inflammation, increased reactive oxidative species, increased fibrosis of muscle, and increased loss of motor neurons, have been reported to contribute to development of sarcopenia by progressing muscle atrophy that results in lower muscle mass (26, 46). These factors have been reported to be tightly controlled by many signaling pathways and effector proteins, including some crosstalk with the protein synthesis pathway (32). Among these signaling pathways, transforming growth factor-β1 (TGF-β1) is considered as the main signaling molecule in the development of sarcopenia (47). TGF-β1 activates many downstream profibrotic signaling molecules, including mothers against decapentaplegic (Smad), extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and p38, which contribute to increasing transdifferentiation of myoblasts into myofibroblasts, resulting in development of muscle atrophy and fibrosis (47). Chronic inflammation has also been considered to contribute to the development of sarcopenia through the production of numerous proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β, which promote muscle catabolism (64).
identified 254 potentially suitable publications. After the removal of duplicates, the titles and abstracts of 98 remaining papers were screened. Of these, 15 publications were excluded because they did not describe specific miRNAs in sarcopenia, and one publication was excluded because it lacked a description of the sample setting; 82 studies were included in the final systematic review (1–82), and 12 studies were included for extracting data (1, 5, 6, 16, 28, 38, 40, 42, 60, 64, 71, 82).

**MicroRNAs in Sarcopenia**

Many studies investigated expression changes of miRNAs in muscles and/or blood (serum or plasma) of patients with sarcopenia (Table 1) and/or animal models of sarcopenia [Table 2; (1, 5, 16, 28, 38, 40, 42, 60, 64, 71, 82)]. Several studies investigated the effects of modulating miRNA expression on phenotypic changes using cultured muscle cells in vitro and rodent models of sarcopenia in vivo [Table 3; (1, 6, 42, 60, 71)].

**Changes of the Expression Levels of microRNAs in Sarcopenia**

Expression of 13 miRNAs (miRNA-10a-3p, –19a, –21, 34a, –92a-3p, 185-3p, 194-3p, –203a-3p, –326, –424-5p, –532-5p, –576-5p, and –760) was found to be changed in the muscles and/or blood (serum or plasma) of patients with sarcopenia [Table 1; (1, 16, 40, 64, 82)]. Among them, expression of three miRNAs in muscle (miRNA-19a, –34a, and –424-5p) (16, 82), eight miRNAs in plasma (miRNA-10a-3p, –92a-3p, –185-3p, –194-3p, –326, –532-5p, –576-5p, and –760) (40), and two miRNAs in serum (miRNA-21 and –203a-3p) (1, 64) was changed and associated with physical functions including shrinking, weakness, poor endurance and energy, slowness, and low physical activity levels and expression of many signaling molecules, such as protein kinase AMP-activated catalytic subunit alpha 1 (PRKA1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), transforming growth factor-β receptor 2 (TGF-βR2), vascular endothelial growth factor A (VEGFA), polymerase I receptor 1A (Pol I R1A), and upstream binding transcription factor (UBTF), which were shown to contribute to sarcopenia development [Table 1; (16, 64, 82)].

Expression of 10 miRNAs (miRNA-1-3p, –29, –29a-3p, –29b-3p, –98-5p, –133a-3p, –133b-3p, –181a, –434-3p, and –455-3p) was changed in muscles of rodent models of sarcopenia [Table 2; (5, 28, 38, 42, 60, 71)]. These miRNAs were associated with the expression levels of many signaling molecules, including tripartite motif containing 63 protein (TRIM63), F-box protein 32 (FBXO32), myeloblastosis-related protein B (B-myb), insulin-like growth factor-1 (IGF-1), p85, nerve growth factor (NGF), sirtuin 1 (Sirt1), eukaryotic translation initiation factor 5A1 (Eif5A1), paired-like homeodomain transcription factor 1 (PITX1), and retinoid X receptor-β (RXRB), which were shown to contribute to sarcopenia development [Table 2; (5, 28, 38, 42, 60, 71)].

**Effects of microRNA Modulation on Sarcopenia**

Several studies have reported that modulation of miRNAs has significant effects on sarcopenia in cultured myocytes in vitro...
### TABLE 1 | Associations between miRNA expression levels and sarcopenia in patients.

| MiRNA     | Samples | Expression change | Details                                                                                                              | Target mRNA                  | References |
|-----------|---------|------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------|------------|
| MiRNA-10a-3p | Plasma  | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-19a  | Muscle  | ↑                | No mention                                                                                                           | PRKAA1 and PFKFB3            | (82)       |
| MiRNA-21   | Serum   | ↑                | The expression level was associated with self-reported exhaustion, time to walk 15 feet, and muscle weight loss        | TGF-βR2                     | (64)       |
| MiRNA-34a  | Muscle  | ↑                | No mention                                                                                                           | VEGFA                       | (82)       |
| MiRNA-92a-3p | Plasma | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-185-3p | Plasma | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-194-3p | Plasma | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-203a-3p | Serum | ↑                | The expression level was associated with the psoas muscle mass index and intramuscular adipose tissue content           | No mention                  | (1)        |
| MiRNA-326  | Plasma  | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-424-5p | Muscle | ↑                | The expression level was associated with the result of 3-m gait speed and 6-m timed up and go test                     | Pol I R1A and UBTF           | (16)       |
| MiRNA-532-5p | Plasma | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-576-5p | Plasma | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |
| MiRNA-760  | Plasma  | ↑                | The expression level was associated with muscle weight loss, grip strength, self-reported exhaustion, time to walk 15 feet, and kilocalories expended per week | No mention                  | (40)       |

* miRNA, microRNA; mRNA, messenger RNA; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; Pol I R1A, polymerase I receptor 1A; PRKAA1, protein kinase AMP-activated catalytic subunit alpha 1; Smad, mothers against decapentaplegic; TGF-βR2, transforming growth factor-β receptor 2; UBTF, upstream binding transcription factor; VEGFA, vascular endothelial growth factor A; ↑ means miRNA’s upregulation in each samples.

(Table 3, Figures 2A,B). The specific miRNAs that have been reported to affect sarcopenia are described below.

### MiRNA-181a

MiRNA-181a binds to the 3′-untranslated region of Sirt1 that is implicated in influencing aging, apoptosis, and inflammation (71). Overexpression of miRNA-181a using an miRNA-181a mimic by lipofection was shown to significantly decrease the myotube diameter, which was mediated by inhibiting its target Sirt1 in cultured myotubes of differentiated C2C12 cells, a subclone of mouse myoblasts. However, miRNA-181a knockdown using a miRNA-181a inhibitor led to an increase in the myotube diameter of cultured myotubes of differentiated C2C12 cells (71).

### MiRNA-203a-3p

MiRNA-203a-3p binds to the 3′-untranslated region of baculoviral inhibitors of apoptosis repeat containing 5 (BIRC5), a member of the apoptosis inhibitor protein family that suppresses apoptosis via inhibition of the initiator caspase 9 and executers caspase 3 and 7 (84). MiRNA-203a-3p was upregulated in serum of colorectal cancer patients with sarcopenia as evaluated by lower psoas muscle mass index compared with than in colorectal cancer patients without sarcopenia (1). Knockdown of miRNA-203a-3p using an miRNA-203-3p mimic by lipofection inhibited cell proliferation and induced apoptosis via increasing the expression level of the target BIRC5 in cultured human skeletal muscle cells (1).

### MiRNA-434-3p

MiRNA-434-3p binds to the 3′-untranslated region of EIf5A1 that is involved in many cellular processes including cell division, apoptosis, and inflammation (60). Overexpression of miRNA-434-3p using an miRNA-434-3p mimic by lipofection inhibited the expression levels of EIf5A1, which prevented apoptosis of apoptosis-stimulated primary myocytes purified from hind limb muscles of C57BL/6J mice (60).
### TABLE 2 | Associations between miRNA expression levels and sarcopenia in rodent models.

| MiRNA      | Sample   | Expression change | Details                                                                  | Target mRNA                  | References |
|------------|----------|-------------------|--------------------------------------------------------------------------|------------------------------|------------|
| MiRNA-1-3p | Muscle   | ↑                 | The expression level was associated with the soleus muscle weight/tibia length index, time to peak twitch tension, maximum tetanic contraction and half relaxation time of twitch, maximum tetanic relaxation rate, and fatigue index | TRIM63 and FBXO32            | (28)       |
| MiRNA-29   | Muscle   | ↑                 | The expression level was associated with extensor digitorum longus and soleus muscle weight losses | B-myb, IGF-1, and p85         | (38)       |
| MiRNA-29a-3p | Muscle | ↑                  | The expression level was associated with the soleus muscle weight/tibia length index, time to peak twitch tension, maximum tetanic contraction and half relaxation time of twitch, maximum tetanic relaxation rate, and fatigue index | TRIM63 and FBXO32            | (28)       |
| MiRNA-29b-3p | Muscle | ↓                  | The expression level was associated with the soleus muscle weight/tibia length index, time to peak twitch tension, maximum tetanic contraction and half relaxation time of twitch, maximum tetanic relaxation rate, and fatigue index | TRIM63 and FBXO32            | (28)       |
| MiRNA-96-5p | Muscle   | ↑                 | The expression level was associated with the size of muscle fibers         | NGF                          | (6)        |
| MiRNA-133a-3p | Muscle | ↑                  | The expression level was associated with the soleus muscle weight/tibia length index, time to peak twitch tension, maximum tetanic contraction and half relaxation time of twitch, maximum tetanic relaxation rate, and fatigue index | TRIM63 and FBXO32            | (28)       |
| MiRNA-133b-3p | Muscle | ↑                  | The expression level was associated with the soleus muscle weight/tibia length index, time to peak twitch tension, maximum tetanic contraction and half relaxation time of twitch, maximum tetanic relaxation rate, and fatigue index | TRIM63 and FBXO32            | (28)       |
| MiRNA-181a | Muscle   | ↓                 | The expression level was associated with the size of myotubes             | Sirt1                        | (71)       |
| MiRNA-434-3p | Muscle | ↓                  | No mention                                                               | E1F5A1                       | (60)       |
| MiRNA-455-3p | Muscle | ↓                  | The expression level was associated with the size of myotubes             | PITX1 and RXRB               | (42)       |

miRNA, microRNA; mRNA, messenger RNA; B-myb, myeloblastosis-related protein B; E1F5A1, eukaryotic translation initiation factor 5A1; FBXO32, F-box protein 32; IGF-1, insulin-like growth factor-1; NGF, nerve growth factor; PITX1, paired-like homeodomain transcription factor 1; RXRB, retinoid X receptor-β; Sirt1, sirtuin 1; Trim63, tripartite motif-containing 63 protein; ↓ means miRNA’s downregulation in each samples; ↑ means miRNA’s upregulation in each samples.

### TABLE 3 | Effects of modulation of miRNA expression on frailty and sarcopenia in cells in vitro and rodent frailty and sarcopenia models in vivo.

| MiRNA      | Tx       | Rodent model and/or cells | Effects                                                                 | Target mRNA                  | References |
|------------|----------|---------------------------|-------------------------------------------------------------------------|------------------------------|------------|
| MiRNA-181a | OE       | Mouse cultured myotubes of differentiated myoblasts (C2C12 cells)    | Inhibition of Sirt1 induced a decrease in the myotube diameter          | Sirt1                        | (71)       |
| MiRNA-203a-3p | OE     | Human skeletal muscle cells | Inhibition of BIRC5 induced a decrease in the number of skeletal muscle cells | BIRC5                        | (1)        |
| MiRNA-434-3p | OE     | Mouse myocytes            | Inhibition of E1F5A1 protected myocytes from apoptosis                   | E1F5A1                       | (60)       |
| MiRNA-455-3p | OE     | Mouse cultured myotubes of differentiated myoblasts (C2C12 cells)    | Inhibition of PITX1 and RXRB induced larger diameters of C2C12 myotubes | PITX1 and RXRB               | (42)       |
| MiRNA-672-5p | OE     | Ovariectomy-induced sarcopenia mouse gastrocnemius muscle            | Inhibition of Atrogin-1 and MuRF1 induced a decrease in lean muscle mass and Feret’s diameter of muscle fibers and increase in the serum creatinine kinase level | Atrogin-1 and MuRF1          | (6)        |

miRNA, microRNA; mRNA, messenger RNA; BIRC, baculoviral inhibitors of apoptosis repeat containing; E1F5A1, eukaryotic translation initiation factor 5A1; MuRF1, muscle ring-finger protein-1; OE, overexpression; PITX1, paired-like homeodomain transcription factor 1; RXRB, retinoid X receptor-β; Sirt1, sirtuin 1; Tx, treatment.
MiRNA-455-3p
Overexpression of miRNA-455-3p using an miRNA-455-3p mimic by lipofection inhibited the expression levels of PITX1 and RXRB, which are involved in muscle dystrophy and aging, resulting in a significant increase of the diameter of cultured myotubes differentiated from cultured mouse C2C12 myoblasts (42).

MiRNA-672-5p
Overexpression of miRNA-672-5p via tail vein injection of an miRNA-672-5p mimic in liposomes alleviated ovariectomy-induced sarcopenia in female BALB/c mice (6). Overexpression of miRNA-672-5p in ovariectomy-induced sarcopenia mice increased lean muscle mass but decreased the serum creatinine kinase level and increased Feret's diameter of muscle fibers with inhibited muscle atrogenes (Atrogin-1 and Murf1) that stimulate protein catabolism and negatively affect muscular health (6). Overexpression of miRNA-672-5p in ovariectomy-induced sarcopenia mice also increased osteoblastogenesis and mineralization, thereby reversing bone loss (6).

DISCUSSION
Many miRNAs increase or decrease in muscles and blood of patients with sarcopenia and rodent models of sarcopenia. These expression changes are associated with the phenotypes of sarcopenia, such as lower physical functions and expression levels of many signaling molecules that mediate progression of sarcopenia. These lines of evidence suggest that miRNA levels in muscles and/or blood are potential biomarkers for sarcopenia. However, no study has reported the relationship between the expression changes of plasma/serum and muscle miRNAs in sarcopenia. It is necessary to investigate this relationship to clarify the mechanisms of miRNAs in each organ including muscles and their circulation form in blood for the development of sarcopenia as well as the utility of miRNAs in blood as biomarkers of sarcopenia. Additionally, several miRNAs have been demonstrated to affect sarcopenia in myocytes in vitro or rodent sarcopenia models in vivo. All studies reported the effects of miRNAs on sarcopenia in the setting of overexpression of these miRNAs as shown in Table 3. These results suggest that miRNAs are potential targets of gene therapy for sarcopenia. However, further studies are needed to investigate the mechanisms, target cells, and adverse effects of modulating these miRNAs. Additionally, so far, there is no clinical study that has directly investigated the functions of miRNAs in sarcopenia by modulation of their expression using a mimic and/or inhibitor. Future clinical studies will be necessary to confirm the effects of miRNAs on sarcopenia and their potential targets for gene therapy of sarcopenia. Our review has a number of limitations. First, we only searched for studies published in English. Second, we only used the PubMed database to identify publications. Third, meta-analysis could not be performed because the number of studies reporting miRNAs for sarcopenia was small, so statistical power would have been low. Therefore, further research is warranted to verify our conclusions.

CONCLUSION
Many miRNAs increase or decrease in muscles and blood of patients with sarcopenia and rodent models of sarcopenia. These expression changes are associated with the phenotypes of sarcopenia, such as lower physical functions and expression levels of many signaling molecules that mediate progression of sarcopenia. These lines of evidence suggest that miRNA levels in muscles and/or blood are potential biomarkers for sarcopenia. However, no study has reported the relationship between the expression changes of plasma/serum and muscle miRNAs in sarcopenia. It is necessary to investigate this relationship to clarify the mechanisms of miRNAs in each organ including muscles and their circulation form in blood for the development of sarcopenia as well as the utility of miRNAs in blood as biomarkers of sarcopenia. Additionally, several miRNAs have been demonstrated to affect sarcopenia in myocytes in vitro or rodent sarcopenia models in vivo. All studies reported the effects of miRNAs on sarcopenia in the setting of overexpression of these miRNAs as shown in Table 3. These results suggest that miRNAs are potential targets of gene therapy for sarcopenia. However, further studies are needed to investigate the mechanisms, target cells, and adverse effects of modulating these miRNAs. Additionally, so far, there is no clinical study that has directly investigated the functions of miRNAs in sarcopenia by modulation of their expression using a mimic and/or inhibitor. Future clinical studies will be necessary to confirm the effects of miRNAs on sarcopenia and their potential targets for gene therapy of sarcopenia. Our review has a number of limitations. First, we only searched for studies published in English. Second, we only used the PubMed database to identify publications. Third, meta-analysis could not be performed because the number of studies reporting miRNAs for sarcopenia was small, so statistical power would have been low. Therefore, further research is warranted to verify our conclusions.
of sarcopenia. Additionally, several miRNAs have been demonstrated to affect sarcopenia in myocytes in vitro or rodent sarcopenia models in vivo. These results suggest that miRNAs are potential biomarkers and targets of gene therapy for sarcopenia. Further studies including clinical studies will be necessary to confirm the utility of miRNAs as biomarkers and targets for gene therapy of sarcopenia.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

1. Okugawa Y, Toyota Y, Hur K, Yamamoto A, Yin C, Ide S, et al. Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. *J Cachexia Sarcopenia Muscle*. (2019) 10:536–48. doi: 10.1002/jcem.12403

2. Rivas DA, Lessard SJ, Rice NP, Lustgarten MS, So K, Goodyear LJ, et al. Diminished skeletal muscle microRNA expression with aging is associated with attenuated muscle plasticity and inhibition of IGF-1 signaling. *FASEB J*. (2014) 28:4133–47. doi: 10.1096/fj.14-254490

3. Narasimhan A, Ghosh S, Stretch C, Greiner R, Bathe OF, Baracos V, et al. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. *J Cachexia Sarcopenia Muscle*. (2017) 8:405–16. doi: 10.1002/jcem.12168

4. Soriano-Arroquia A, McCormick R, Molloy AP, McArdle A, Goljanek-Whysall K. Age-related changes in miR-143-3p:Igfbp5 interactions affect muscle regeneration. *Aging Cell*. (2016) 15:361–9. doi: 10.1111/acel.12442

5. Aare S, Spendiff S, Vuda M, Elkrief D, Perez A, Wu Q, et al. Failed reinervation in aging skeletal muscle. *Skelet Muscle*. (2016) 6:29. doi: 10.1186/s13395-016-0101-y

6. Ahmad N, Kushwaha P, Karvande A, Tripathi AK, Kothari P, Adhikary S, et al. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. *Trials*. (2018) 19:6. doi: 10.1186/s13063-017-2390-9

7. Altana V, Geretto M, Pulliero A. MicroRNAs and physical activity. *Microrna*. (2015) 4(7):4–85. doi: 10.2174/2211536604666150813152450

8. Assar ME, Angulo J, Rodriguez-Manas L. Diabetes and ageing-induced vascular inflammation. *J Physiol*. (2016) 594:2125–46. doi: 10.1113/jp270841

9. Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, et al. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. *Trials*. (2018) 70. doi: 10.1186/s13063-017-2390-9

10. Barber L, Scicchitano BM, Musaro A. Molecular and cellular mechanisms of muscle aging and sarcopenia and effects of electrical stimulation in seniors. *Eu J Transl Myol*. (2015) 25:331–6. doi: 10.4081/ejtm.2015.5227

11. Berardi E, Annibali D, Cassano M, Crippa S, Sampaloesi M. Molecular and cell-based therapies for muscle degenerations: a road under construction. *Front Physiol*. (2014) 5:119. doi: 10.3389/fphys.2014.00119

12. Borras C, Serna E, Gambini J, Ingles M, Vina J. Centenarians maintain miRNA biogenesis pathway while it is impaired in octogenarians. *Mol Ageing Dev*. (2017) 16:54–7. doi: 10.1002/j.mad.2017.07.003

13. Brown DM, Goljanek-Whysall K. microRNAs: modulators of the underlying pathophysiology of sarcopenia? *Ageing Res Rev*. (2015) 24(Pt B):263–73. doi: 10.1016/j.arr.2015.08.007

14. Cardoso AL, Fernandes A, Aguilar-Pimentel JA, de Angelis MH, Guedes JR, Brito MA, et al. Towards frailty biomarkers: candidates from genes and pathways regulated in aging and age-related diseases. *Ageing Res Rev*. (2018) 47:214–77. doi: 10.1016/j.arr.2018.07.004

15. Chen Z, Bembem MG, Bembem DA. Bone and muscle specific circulating microRNAs in postmenopausal women based on osteoporosis and sarcopenia status. *Bone*. (2019) 120:271–8. doi: 10.1016/j.bone.2018.11.001

16. Connolly M, Paul R, Farre-Garros R, Natanek SA, Bloch S, Lee J, et al. miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting. *J Cachexia Sarcopenia Muscle*. (2018) 9:400–16. doi: 10.1002/jcem.12166

17. Cull AH, Raub MJ. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes. *J Leukoc Biol*. (2017) 102:209–19. doi: 10.1189/jlb.5RI03 17-083R

18. Dalmasso B, Hatse S, Brouwers B, Laenen A, Berlen B, Kenis C, et al. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. *BM C Cancer*. (2018) 18:1014. doi: 10.1186/s12885-018-4920-6

19. Dato S, Rose G, Crocco P, Monti D, Garagnani P, Franceschi C, et al. The genetics of human longevity: an intricacy of genes, environment, culture and microbiome. *Molec Aging Dev*. (2017) 165(Pt B):147–55. doi: 10.1016/j.molage.2017.03.011

20. Di Filippo ES, Mancinelli R, Pietrangelo T, La Rovere RM, Quattrocieli M, Sampaloesi M, et al. Myomir dysregulation and reactive oxygen species in aged human satellite cells. *Biochem Biophys Res Commun*. (2016) 473:462–70. doi: 10.1016/j.bbrc.2016.03.030

21. Drummond MJ, McCarthy JJ, Fry CS, Esser KA, Rasmussen BB. Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. *Am J Physiol Endocrinol Metab*. (2008) 295:E1333–40. doi: 10.1152/ajpendo.90562.2008

22. Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA, et al. Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. *Physiol Genomics*. (2011) 43:595–603. doi: 10.1152/physiolgenomics.00148.2010

23. D’Souza RF, Zeng N, Markworth JF, Figueiredo VC, Hedges CP, Petersen AC, et al. Whey protein supplementation post resistance exercise in elderly men induces changes in muscle miRNAs compared to resistance exercise alone. *Front Nutr*. (2019) 6:91. doi: 10.3389/fnut.2019.00091

24. Ebner N, Nanker SD, von Haehling S. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th cachexia conference. *J Cachexia Sarcopenia Muscle*. (2019) 10:218–25. doi: 10.1002/jcem.12408

25. Erusalimsky JD, Grillari J, Grune T, Varga EV, von Haehling S, et al. In search of ‘omics’-based biomarkers to predict risk of frailty and its consequences in older individuals: the FRAILOMIC initiative. *Gerontology*. (2016) 62:182–90. doi: 10.1159/000453853

FUNDING

This review was supported by AMED under Grant No. JP19ek0210094h0003 and JSPS KAKENHI under Grant No. JP17K09708.

ACKNOWLEDGMENTS

We thank Mitchell Arico from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.00180/full#supplementary-material
26. Fan J, Kou X, Yang Y, Chen N. MicroRNA-regulated proinflammatory cytokines in sarcopenia. Mediat Inflamm. (2016) 2016:1438686. doi: 10.1155/2016/1438686

27. Fariyike B, Singleton Q, Hunter M, Hill WD, Isales CM, Hamrick MW, et al. Role of MicroRNA-141 in the aging musculoskeletal system: a current overview. Mech Ageing Dev. (2019) 178:9–15. doi: 10.1016/j.mad.2018.12.001

28. Gerlinger-Romero F, Yonamine CY, Junior DC, Esteves JV, Machado UF. Dysregulation between TRIM63/FBXO32 expression and soleus muscle wasting in diabetic rat potential role of mir-1-3p, −29a/b-3p, and −133b-3p. Mol Cell Biochem. (2017) 427:187–99. doi: 10.1007/s11010-016-2910-z

29. Goljaneh-Whysall K, Iwanjeiko LA, Vasilaki A, Pekovic-Vaughan V, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. J Cachexia Sarcopenia Muscle. (2016) 7:330–44. doi: 10.1007/jcsm.12078

30. Graham ZA, De Gasperi R, Bauman WA, Cardozo CP. Recombinant

31. Ibanez-Ventoso C, Driscoll M. MicroRNAs in C. elegans

32. Gumucio JP, Mendias CL. Atrogin-1, MuRF-1, and sarcopenia.

33. Hatse S, Brouwers B, Dalmasso B, Laenen A, Kenis C, Schoffski P, et al. Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS ONE. (2014) 9:e110644. doi: 10.1371/journal.pone.0110644

34. Hu G, Liao K, Yang L, Pendyala G, Kook Y, Fox HS, et al. T regeneration of miRs-34a & 138 promotes astrocytic activation via downregulation of SIRT1: implications for aging in HAND. J Neuroimmunol Pharmacol. (2017) 12:420–32. doi: 10.1007/s11481-017-9730-0

35. Ipson BR, Fletcher MB, Espinoza SE, Fisher AL. Identifying exosome-derived MicroRNAs in the aging brain: a review. Neurobiol Aging. (2017) 58:61–76. doi: 10.1016/j.neurobiolaging.2016.11.013

36. Ibanez-Ventoso C, Driscoll M. MicroRNAs in C. elegans

37. Hu G, Kwon ES, Kwon KS. Molecular mechanisms and regulatory networks in aging. J Mol Med. (2017) 95:945–66. doi: 10.1007/s00109-017-2451-1

38. Hu Z, Klein JD, Atrogin-1, MuRF-1, and sarcopenia. Endocrine. (2013) 43:12–21. doi: 10.1007/s12020-012-9571-7

39. Ibanez-Ventoso C, Driscoll M. MicroRNAs in C. elegans

40. Ibanez-Ventoso C, Driscoll M. MicroRNAs in C. elegans

41. Jung HJ, Lee KP, Kwon KS, Yonamine CY, Junior DC, Esteves JV, Machado UF. Dysregulation between TRIM63/FBXO32 expression and soleus muscle wasting in diabetic rat potential role of mir-1-3p, −29a/b-3p, and −133b-3p. Mol Cell Biochem. (2017) 427:187–99. doi: 10.1007/s11010-016-2910-z

42. Goljaneh-Whysall K, Iwanjeiko LA, Vasilaki A, Pekovic-Vaughan V, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. J Cachexia Sarcopenia Muscle. (2016) 7:330–44. doi: 10.1007/jcsm.12078

43. Macdonald EM, Cohen BD. TGFbeta signaling: its role in fibrosis formation and myopathies. Curr Opin Rheumatol. (2012) 24:628–34. doi: 10.1097/BOR.0b013e328353d8f4

44. Margolis LM, Dawson-Hughes B, Rivas DA, Ezzyat Y, Fielding RA, Ceglia L. Effects of potassium bicarbonate supplements on circulating microRNA expression. J Endocr Soc. (2017) 1:1015–26. doi: 10.1210/jc.2017-00106

45. Margolis LM, Lissar SG, Ezzyat Y, Fielding RA, Rivas DA. Circulating MicroRNAs are predictive of aging and acute adaptive response to resistance exercise in men. J Gerontol A Biol Sci Med Sci. (2017) 72:1319–26. doi: 10.1093/gerona/glw243

46. Margolis LM, Rivas DA. Potential role of MicroRNA in the anabolic capacity of skeletal muscle with aging. Exerc Sport Sci Rev. (2018) 46:86–91. doi: 10.1249/ESS.0000000000000147

47. Margolis LM, Rivas DA, Barrone M, Ezzyat Y, Young AJ, McClung JP, et al. Prolonged calorie restriction downregulates skeletal muscle miRTOC signaling independent of dietary protein intake and associated microRNA expression. Front Physiol. (2016) 7:445. doi: 10.3389/fphys.2016.00445

48. McGregor RA, Poppitt SD, Cameron-Smith D. Role of microRNAs in the age-related changes in skeletal muscle and diet or exercise interventions to promote healthy aging in humans. Ageing Res Rev. (2014) 17:25–33. doi: 10.1016/j.ager.2014.05.001

49. Meng XM, Tan PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. Front Physiol. (2015) 6:682. doi: 10.3389/fphys.2015.00082

50. Michalska-Kasizak M, Bielecka-Dabrowa A, von Haeling S, Anker SD, Rysz J, Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci. (2018) 14:890–909. doi: 10.1142/aoms.2018.76279

51. Mikovic J, Sadler K, Butchart I, Voisin S, Gerlinger-Romero F, Dela Gatta P, et al. MicroRNA and long non-coding RNA regulation in skeletal muscle from growth to old age shows striking dysregulation of the calpyppe locus. Front Genet. (2016) 9:548. doi: 10.3389/fgene.2018.00548

52. Mitchell CJ, D’Souza RF, Schierding W, Zeng N, Ramzan F, O’Sullivan JM, et al. Identification of human skeletal muscle microRNA related to strength by high-throughput sequencing. Physiol Genomics. (2018) 50:416–24. doi: 10.1152/physiogenomics.00112.2017

53. Montano M, Long K. MicroRNA surveillance-an emerging role for RNA regulatory networks in aging. Ageing Res Rev. (2011) 10:216–24. doi: 10.1016/j.arr.2010.02.002

54. Nie M, Deng ZL, Liu J, Wang DZ. Noncoding RNAs, emerging regulators in skeletal muscle development and diseases. Biomed Res Int. (2015) 2015:675575. doi: 10.1155/2015/675575

55. Okugawa Y, Yao L, Toiyama Y, Yamamoto A, Shimogori T, Yin C, et al. Prognostic impact of sarcopenia and its correlation with circulating miR-21 in colorectal cancer patients. Oncol Rep. (2018) 39:1555–64. doi: 10.3892/or.2018.6270

56. Pardo PS, Hajira A, Boriek AM, Mohamed JS. MicroRNA-434-3p regulates age-related apoptosis through eIF3A1 in the skeletal muscle. Aging. (2017) 9:1012–29. doi: 10.18632/aging.101207

57. Park SS, Kwon ES, Kwon KS. Molecular mechanisms and therapeutic interventions in sarcopenia. Osteoporos Sarcopenia. (2017) 3:117–22. doi: 10.1016/j.jofs.2017.08.098

58. Portal-Nunez S, Esbrit P, Alcaraz MJ, Largo R. Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis. Biochem Pharmacol. (2016) 108:1–10. doi: 10.1016/j.bcp.2015.12.012

59. Proctor CJ, Goljaneh-Whysall K. Using computer simulation models to investigate the most promising microRNAs to improve muscle regeneration during ageing. Sci Rep. (2017) 7:12314. doi: 10.1038/s41598-017-12538-6

60. Rusanova I, Diaz-Casado ME, Fernandez-Ortiz M, Aranda-Martinez P, Guerra-Libero A, Garcia-Garcia FJ, et al. Analysis of plasma MicroRNAs as predictors and biomarkers of aging and frailty in humans. Oxid Med Cell Longev. (2018) 2018:761850. doi: 10.1155/2018/761850
65. Rusanova I, Fernandez-Martinez J, Fernandez-Ortiz M, Aranda-Martinez P, Escames G, Garcia-Garcia FJ, et al. Involvement of plasma miRNAs, muscle miRNAs and mitochondrial miRNAs in the pathophysiology of frailty. *Exp Gerontol.* (2019) 124:110637. doi: 10.1016/j.exger.2019.110637
66. Sannicandro AJ, Soriano-Arroquia A, Goljanek-Whysall K. micro(RNA)-managing muscle wasting. *J Appl Physiol.* (1985) 127:619–32. doi: 10.1152/japplphysiol.00961.2018
67. Sarkozy M, Kovacs ZZA, Kovacs MG, Gaspar R, Szucs G, Dux L. Mechanisms and modulation of oxidative/nitrative stress in type 4 cardio-renal syndrome and renal sarcopenia. *Front Physiol.* (2018) 9:1648. doi: 10.3389/fphys.2018.01648
68. Seldeen KL, Pang M, Leiker MM, Bard JE, Rodriguez-Gonzalez M, Hernandez M, et al. Chronic vitamin D insufficiency impairs physical performance in C57BL/6j mice. *Aging.* (2018) 10:1338–55. doi: 10.18632/aging.101471
69. Shorter E, Sannicandro AJ, Poulet B, Goljanek-Whysall K. Skeletal muscle wasting and its relationship with osteoarthritis: a mini-review of mechanisms and current interventions. *Curr Rheumatol Rep.* (2019) 21:40. doi: 10.1007/s11926-019-0839-4
70. Siracusa J, Koulmann N, Banzet S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. *J Cachexia Sarcopenia Muscle.* (2018) 9:20–7. doi: 10.1002/jcsm.12227
71. Soriano-Arroquia A, House L, Tregilgas L, Canty-Laird E, Goljanek-Whysall K. The functional consequences of age-related changes in microRNA expression in skeletal muscle. *Biogerontology.* (2016) 17:641–54. doi: 10.1007/s10522-016-9638-8
72. Suzuki T, Springer J. MicroRNAs in muscle wasting. *J Cachexia Sarcopenia Muscle.* (2018) 9:1209–12. doi: 10.1002/jcsm.12384
73. Swan M. Meeting report: American aging association 40th Annual Meeting, Raleigh, North Carolina, June 3–6, 2011. *Rejuvenation Res.* (2011) 14:449–55. doi: 10.1089/rej.2011.12126
74. Tan LJ, Liu XL, Lei SF, Papasian CJ, Deng HW. Molecular genetic studies of gene identification for sarcopenia. *Hum Genet.* (2012) 131:1–31. doi: 10.1007/s00439-011-1040-7
75. Trovato E, Di Felice V, Barone R. Extracellular vesicles: delivery vehicles of myokines. *Front Physiol.* (2019) 10:522. doi: 10.3389/fphys.2019.00522
76. Wang E. MicroRNA, the putative molecular control for mid-life decline. *Ageing Res Rev.* (2007) 6:1–11. doi: 10.1016/j.arr.2007.02.004
77. Weigl LG. Lost in translation: regulation of skeletal muscle protein synthesis. *Curr Opin Pharmacol.* (2012) 12:377–82. doi: 10.1016/j.coph.2012.02.017
78. Weilner S, Grillari-Voglauer R, Redl H, Grillari J, Nau T. The role of microRNAs in cellular senescence and age-related conditions of cartilage and bone. *Acta Orthop.* (2015) 86:92–9. doi: 10.3109/17453674.2014.97079
79. Yanai K, Ishii H, Aomatsu A, Ishibashi K, Morishita Y. MicroRNAs in peritoneal fibrosis: a systematic review. *Discof Med.* (2018) 26:271–80.
80. Zeng N, D’Souza RF, Mitchell CJ, Cameron-Smith D. Sestrins are differentially expressed with age in the skeletal muscle of men: a cross-sectional analysis. *Exp Gerontol.* (2018) 110:23–34. doi: 10.1016/j.exger.2018. 05.006
81. Zeng P, Han W, Li C, Li H, Zhu D, Zhang Y, et al. miR-378 attenuates muscle regeneration by delaying satellite cell activation and differentiation in mice. *Acta Biochim Biophys Sin.* (2016) 48:833–9. doi: 10.1093/abbs/gmw077
82. Zheng Y, Kong J, Li Q, Wang Y, Li J. Role of miRNAs in skeletal muscle aging. *Clin Interv Aging.* (2018) 13:2407–19. doi: 10.2147/CIA.S169202
83. Shamseer L, Moher D, Clarke M, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* (2015) 350:g7647. doi: 10.1136/bmj.g7647
84. Kotipatruni RR, Nalla AK, Asuthkar S, Gondi CS, Dinh DH, Rao JS. Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastoma. *PLoS ONE.* (2012) 7:e4798. doi: 10.1371/journal.pone.004798

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yanai, Kaneko, Aomatsu, Ito, Hirai, Ookawara, Ishibashi and Morishita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.